Cadrenal Therapeutics, Inc. Common Stock (CVKD)
$
5.81
+0.09 (1.55%)
Key metrics
Financial statements
Free cash flow per share
-5.7896
Market cap
13.6 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
3.0160
Income quality
0.8218
Average inventory
0
ROE
-2.7952
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company focused on advancing its innovative therapy, Tecarfarin, which has received orphan drug designation for preventing systemic thromboembolism of cardiac origin in patients suffering from end-stage renal disease and atrial fibrillation. The company was established in 2022 and is based in Ponte Vedra, Florida. In its financial performance, the net total of other income and expenses is $309,251.00 reflecting non-core financial activities that could impact overall profitability. The income before tax ratio stands at 0.00 indicating the pre-tax margin achieved by the company during its operations. Investors will find that the company's stock is identified with the symbol 'CVKD' in the market, providing a straightforward way to track its performance. Additionally, the diluted EPS is -$8.73 which takes into account any potential share dilution that might affect earnings per share. It is noteworthy that the company incurred an interest expense of $0.00 which reflects its commitments to debt servicing and can influence cash flow management. Looking at the investment landscape, the stock is affordable at $13.17 making it suitable for budget-conscious investors who are exploring opportunities in the biopharmaceutical sector. However, it exhibits a low average trading volume of 55,990.00 indicating lower market activity which may impact liquidity and volatility. With a market capitalization of $13,584,518.00 the company is classified as a small-cap player within its industry. Cadrenal is a key player in the Biotechnology industry, where it contributes significantly to the overall market landscape by driving innovation and therapeutic advancements. Furthermore, it belongs to the Healthcare sector, a vital part of the economy, and is dedicated to fostering growth and development in its field.
Is Cadrenal Therapeutics, Inc. Common Stock (CVKD) a good investment?
Investing in Cadrenal Therapeutics, Inc. Common Stock (CVKD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Cadrenal Therapeutics, Inc. Common Stock (CVKD)'s stock forecast?
Analysts predict Cadrenal Therapeutics, Inc. Common Stock stock to fluctuate between $5.34 (low) and $22.90 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cadrenal Therapeutics, Inc. Common Stock's market capitalization?
As of 2026-02-10, Cadrenal Therapeutics, Inc. Common Stock's market cap is $13,584,518, based on 2,338,127 outstanding shares.
How does Cadrenal Therapeutics, Inc. Common Stock compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Cadrenal Therapeutics, Inc. Common Stock has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock?
To buy Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CVKD. Place an order (Market, Limit, etc.).
What is the best time to invest in Cadrenal Therapeutics, Inc. Common Stock?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Cadrenal Therapeutics, Inc. Common Stock stock ever split?
Cadrenal Therapeutics, Inc. Common Stock's last stock split was 1:15 on 2024-08-20.
How did Cadrenal Therapeutics, Inc. Common Stock perform in the last earnings report?
Revenue: $0 | EPS: -$8.73 | Growth: -9.35%.
Where can I find Cadrenal Therapeutics, Inc. Common Stock's investor relations reports?
Visit https://www.cadrenal.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cadrenal Therapeutics, Inc. Common Stock?
You can explore historical data from here
What is the all-time high and low for Cadrenal Therapeutics, Inc. Common Stock stock?
All-time high: $101.25 (2023-01-20) | All-time low: $5.34 (2026-02-05).
What are the key trends affecting Cadrenal Therapeutics, Inc. Common Stock stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a month ago
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today highlighted the significant and persistent unmet medical need in heparin-induced thrombocytopenia (HIT) and underscored the promise of its recently acquired investigational drug candidate, VLX-1005, the first and only potent, highly selective 12-LOX inhibitor in clinical testing as a potential new treatment option. Cadrenal Therapeutics acquired VLX-1005 in December 2025, recognizing its potential to transform the treatment landscape for HIT and other immune-mediated thrombotic disorders.
defenseworld.net
a month ago
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $6.97, for a total transaction of $69,233.01. The sale was disclosed in a document filed with the SEC, which is available at
accessnewswire.com
a month ago
PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they see opportunity. Others step in because the situation has become unsustainable, and someone has to fix it.
accessnewswire.com
a month ago
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods.
defenseworld.net
a month ago
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 61,671 shares, a growth of 84.0% from the November 30th total of 33,512 shares. Based on an average trading volume of 75,114 shares,
defenseworld.net
a month ago
IN8bio (NASDAQ: INAB - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Risk and Volatility IN8bio has a beta of
defenseworld.net
2 months ago
Biodexa Pharmaceuticals (NASDAQ: BDRX - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Insider and Institutional Ownership 17.5% of Biodexa
globenewswire.com
2 months ago
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that members of its management team, including Quang X.
accessnewswire.com
2 months ago
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ: CVKD ) entered the back half of the year with a calm, almost surgical approach to building out its foundation. While most microcaps lean on noise to stay visible, Cadrenal has let its work do the lifting.
accessnewswire.com
2 months ago
PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused.
See all news
